Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).
Laurence Albiges, MD
Advertisement
Articles by Laurence Albiges, MD
Laurence Albiges, MD, medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses how immunotherapy has had an impact on the field of renal cell carcinoma (RCC).
Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses how oncologists can treat patients with metastatic renal cell carcinoma (mRCC) based off of findings from a study that looked at the impact of body mass index (BMI) on outcomes of these patients.
Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).
Advertisement
Latest Updated Articles
Dr. Albiges on Immunotherapy in Renal Cell CarcinomaPublished: October 18th 2016 | Updated:
Dr. Albiges on Next Steps for Immunotherapy in RCCPublished: August 18th 2017 | Updated:
Dr. Albiges on Implementing mRCC Findings into PracticePublished: April 16th 2015 | Updated:
Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCCPublished: February 26th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5